Sientra Launches New miraDry fresh™ Protocol for the miraDry® System at American Academy of Dermatology Annual Meeting
February 16 2018 - 8:30AM
miraDry, Inc., a subsidiary of Sientra, Inc. (NASDAQ:SIEN)
(“Sientra” or the “Company”), a medical aesthetics company, today
announced the launch of a new, improved treatment protocol for the
miraDry system. Launching at the American Academy of
Dermatology (AAD) Annual Meeting in San Diego, CA, February
16-18, 2018, the new miraDry fresh protocol reduces overall
procedure time by up to 35%, resulting in a treatment that can be
administered with greater ease and is more delegateable.
The miraDry treatment is the first and only
FDA-cleared solution to permanently reduce underarm sweat, odor and
hair of all colors with as little as one treatment, in one hour
with immediate results. The new, optimized miraDry fresh treatment
protocol and software upgrade offers miraDry providers several
significant benefits:
- Overall procedure time reduced by up to 35%, enabling miraDry
treatments to be performed in one hour or less
- Revised anesthesia process, that is simpler, faster and enables
the treatment to be delegated more easily
- Simplified template designs that better conforms to miraDry
clinician needs and usage patterns. The new Template System is now
consolidated into only four treatment templates and offers an
improved visual design which simplifies the procedure, increases
ease of use and provides better tattoo transfer to the treatment
area.
The miraDry fresh protocol is the second
innovation within three years to bring greater value to existing
miraDry providers worldwide.
"Patient and provider satisfaction will continue
to drive our product advancements at miraDry," explained Keith J.
Sullivan, General Manager at miraDry. "For miraDry patients,
this means delivering the expected miraDry results, and fitting it
within their lifestyle. For our miraDry providers, this means
continuing to advance the original miraDry system by offering an
upgraded system and protocol that enables them to deliver the
miraDry procedure they trust with even greater ease and confidence,
but with less hands-on treatment time."
To learn more about the miraDry procedure and
the new miraDry fresh protocol, visit the miraDry booth at AAD
(Booth #2455) in the San Diego Convention Center during exhibit
hours 10 a.m. to 5 p.m. on February 16-17, and 10 a.m. to 3 p.m. on
February 18.
About the miraDry ProcedureThe
miraDry procedure is a non-surgical, clinically-proven procedure
that permanently reduces sweat, odor and hair using thermal
energy. The miraDry procedure is FDA-cleared. It is available
in the United States for the non-invasive treatment of unwanted
underarm sweat, odor and hair. In international markets, miraDry is
indicated for excessive underarm sweat. The miraDry procedure
results in immediate results with as little as one treatment, with
little to no downtime, in one hour. As sweat glands in the
treated areas are gone for good, miraDry offers a permanent
reduction of excess sweat with lasting efficacy. Clinical data
demonstrates 100% of patients without bothersome sweat at 1- and
2-year- post treatment.1
Over 100,000 miraDry treatments have been
performed by over 950 providers worldwide. The miraDry treatment
garners high patient satisfaction with a 90% all-time “Worth It”
rating on RealSelf.com2. The miraDry procedure is available through
an elite network of miraDry providers worldwide. Dermatologists,
plastic surgeons and leading aesthetic specialists that offer
miraDry can be found at www.miraDry.com.
Be sure to follow miraDry:
Facebook, Twitter, Pinterest and YouTube.
1. Lupin et al. Long-term
efficacy and quality of life assessment for treatment of axillary
hyperhidrosis with a microwave device. Dermatol Surg 40: 805-807
(2014). 2. RealSelf miraDry “Worth It” ratings
over all time, sourced January 16, 2018
About SientraHeadquartered in
Santa Barbara, California, Sientra is a medical aesthetics company
committed to making a difference in patients’ lives by enhancing
their body image, growing their self-esteem and restoring their
confidence. The Company was founded to provide greater choice to
board-certified plastic surgeons and patients in need of medical
aesthetics products. The Company has developed a broad portfolio of
products with technologically differentiated characteristics,
supported by independent laboratory testing and strong clinical
trial outcomes. The Company sells its breast implants and breast
tissue expanders exclusively to board-certified and
board-admissible plastic surgeons and tailors its customer service
offerings to their specific needs. The Company also offers a
range of other aesthetic and specialty products including
BIOCORNEUM®, the professional choice in scar management, and
miraDry, the only FDA cleared device to reduce underarm sweat, odor
and permanently reduce hair of all colors.
Forward Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
based on management’s current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and actual
results may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements include, but are not limited to,
statements regarding the ability of the miraDry fresh protocol to
reduce overall procedure time, the ability of the miraDry to
conform to clinician needs, the Company’s ability to advance the
miraDry system and the Company’s ability to successfully
commercialize the system. Such statements are subject to risks and
uncertainties, including the dependence on positive reaction from
clinicians and their patients. Additional factors that could cause
actual results to differ materially from those contemplated in this
press release can be found in the Risk Factors section of Sientra’s
most recently filed Quarterly Report on Form 10-Q and its Annual
Report on Form 10-K for the year ended December 31, 2016. All
statements other than statements of historical fact are
forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’
‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’
‘‘continue,’’ ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ or
the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes are intended to identify
estimates, projections and other forward-looking statements.
Estimates, projections and other forward-looking statements speak
only as of the date they were made, and, except to the extent
required by law, the Company undertakes no obligation to update or
review any estimate, projection or forward-looking statement.
Investor Contacts:
Patrick F. WilliamsSientra, Chief Financial
Officer (619) 675-1047patrick.williams@sientra.com
Tram Bui / Brian JohnstonThe Ruth Group(646)
536-7035 / (646) 536-7028IR@sientra.com
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Apr 2023 to Apr 2024